8-K: Marpai Inc. Secures $1.5 Million in Private Placement with CEO-Controlled Fund

Marpai Inc. has entered into a securities purchase agreement to sell 910,000 shares of its Class A common stock at $1.65 per share to HillCour Investment Fund, LLC, an entity controlled by its CEO.

Summary

• Marpai Inc. has agreed to sell 910,000 shares of its Class A common stock in a private placement.
• The shares are being sold to HillCour Investment Fund, LLC, an entity controlled by Marpai's CEO, Damien Lamendola.
• The purchase price is $1.65 per share, totaling approximately $1,501,500.
• The transaction is exempt from registration under the Securities Act of 1933.
• The agreement was finalized on March 7, 2024, with the closing expected shortly thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company secured funding, the related-party nature of the transaction and potential dilution of existing shareholders temper the positive aspects.

Positives

• The private placement provides Marpai with $1.5 million in funding.
• The CEO's participation demonstrates confidence in the company's prospects.
• The transaction was completed quickly, with the agreement signed on March 7, 2024.

Negatives

• The private placement dilutes existing shareholders' ownership.
• The sale is to an entity controlled by the CEO, which could raise conflict of interest concerns.

Risks

• The securities are not registered and may not be easily resold.
• The transaction could be perceived negatively by the market due to the related-party nature of the deal.
• The company's reliance on private placements for funding may indicate underlying financial challenges.

Future Outlook

The company intends to use the proceeds from the private placement for general corporate purposes, but no specific details were provided.

Management Comments

• The agreement was signed by Damien Lamendola, Chief Executive Officer of Marpai Inc.

Industry Context

Private placements are a common method for companies to raise capital, particularly for smaller or growth-stage companies. The involvement of the CEO's fund is not unusual but warrants scrutiny for potential conflicts of interest.

Comparison to Industry Standards

• The pricing of the private placement at the closing bid price is a common practice to ensure fair market value.
• Private placements are often used by companies that may not have access to traditional bank financing or public markets.
• The size of the placement, $1.5 million, is relatively small compared to larger capital raises in the healthcare technology sector.
• Comparable companies in the healthcare technology space often use a mix of debt and equity financing to fund operations and growth.

Related Party Transactions

• The private placement involves HillCour Investment Fund, LLC, an entity controlled by Marpai's CEO, Damien Lamendola.

Stakeholder Impact

• Existing shareholders will experience dilution of their ownership due to the issuance of new shares.
• The company's financial position is strengthened by the infusion of capital.
• The transaction could raise concerns among some investors due to the related-party nature of the deal.

Next Steps

• The company will deliver the shares to the purchaser.
• The company will file a Form D with the SEC.
• The company will seek to list the shares on the applicable trading market.

Key Dates

Keywords

private placement, equity financing, securities purchase agreement, common stock, HillCour Investment Fund, Damien Lamendola, Marpai Inc., capital raise